Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases
Jonatan Barrera‐Chimal, Benjamin Bonnard, Frédéric Jaisser
Annual Review of Physiology (2022) Vol. 84, Iss. 1, pp. 585-610
Closed Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Properties and Functions of Fibroblasts and Myofibroblasts in Myocardial Infarction
Harikrishnan Venugopal, Anis Hanna, Claudio Humeres, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1386-1386
Open Access | Times Cited: 129
Arterial Stiffness: From Basic Primers to Integrative Physiology
Véronique Regnault, Patrick Lacolley, Stéphane Laurent
Annual Review of Physiology (2024) Vol. 86, Iss. 1, pp. 99-121
Open Access | Times Cited: 16
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong‐Lim Kim, Seung‐Eun Lee, Nan Hee Kim
Endocrinology and Metabolism (2023) Vol. 38, Iss. 1, pp. 43-55
Open Access | Times Cited: 27
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
Ruolin Lv, Lili Xu, Lin Che, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 25
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3969-3969
Open Access | Times Cited: 13
New insights in the treatment of DKD: recent advances and future prospects
Meimei Zhao, Yongtong Cao, Liang Ma
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Slowing the Progression of Diabetic Kidney Disease
Olivia Blazek, George L. Bakris
Cells (2023) Vol. 12, Iss. 15, pp. 1975-1975
Open Access | Times Cited: 16
Present and future of drug therapy in hypertension: an overview
Josep Redón, Rafael Carmena
Blood Pressure (2024) Vol. 33, Iss. 1
Open Access | Times Cited: 6
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Jawad H. Butt, Alasdair Henderson, Pardeep S. Jhund, et al.
Journal of the American College of Cardiology (2024) Vol. 85, Iss. 2, pp. 140-155
Open Access | Times Cited: 6
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
Peter Kolkhof, Robert Lawatscheck, Gerasimos Filippatos, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9243-9243
Open Access | Times Cited: 25
Tissular glucocorticoid reactivating enzyme 11beta-HSD1 drives pathogenic myofibroblast differentiation in chronic kidney disease
Grégoire Arnoux, David Legouis, Matthieu Tihy, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
Merita Rroji, Nereida Spahia, Andreja Figurek, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 728-728
Open Access
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
Ralph A. DeFronzo, George L. Bakris
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1197-1205
Open Access | Times Cited: 20
A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
Shuhui Zhai, Baisheng Ma, Weiwei Chen, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 3
The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
Xinping Chen, Xuan Li, Kexin Zhang, et al.
Clinical and Experimental Nephrology (2023) Vol. 28, Iss. 2, pp. 125-135
Closed Access | Times Cited: 8
Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction
Aderonke E. Igbekele, George Jia, Michael A. Hill, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 8954-8954
Open Access | Times Cited: 13
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
Monarch Shah, Alaa S. Awad, Emaad M. Abdel‐Rahman
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6285-6285
Open Access | Times Cited: 7
XBP1 Modulates the Aging Cardiorenal System by Regulating Oxidative Stress
Ji Zhang, Yuanyuan Zhao, Nianqiao Gong
Antioxidants (2023) Vol. 12, Iss. 11, pp. 1933-1933
Open Access | Times Cited: 7
Mineralocorticoid promotes intestinal inflammation through receptor dependent IL17 production in ILC3s
Rongchuan Zhao, Hong Lei, Guohua Shi, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111678-111678
Closed Access | Times Cited: 2
Mineralocorticoid receptor antagonists and reno‐protection: What's the evidence & where do they fit? A guide for non‐specialists
George L. Bakris
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 33-42
Open Access | Times Cited: 2
The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
Mustafa Kemal Arıcı, Bulent Altun, Mustafa Araz, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Association between Use of Spironolactone and Risk of Stroke in Hypertensive Patients: A Cohort Study
Xintian Cai, Nanfang Li
Pharmaceuticals (2022) Vol. 16, Iss. 1, pp. 57-57
Open Access | Times Cited: 9
Lymphatic vessels and the renin-angiotensin-system
Giovanni Bertoldi, Ilaria Caputo, Lorenzo A. Calò, et al.
AJP Heart and Circulatory Physiology (2023) Vol. 325, Iss. 4, pp. H837-H855
Closed Access | Times Cited: 5
Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure
Jonathan D. Ravid, Luke J. Laffin
Current Cardiology Reports (2022) Vol. 24, Iss. 10, pp. 1251-1259
Closed Access | Times Cited: 8
Novel Therapies on the Horizon of Hypertension Management
Olivia Blazek, George L. Bakris
American Journal of Hypertension (2022) Vol. 36, Iss. 2, pp. 73-81
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top